Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)

被引：0

作者：

Motzer, Robert J.

机构：

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期

关键词：

D O I：

10.1200/JCO.23.00901

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3767 / 3767

页数：1

共 50 条

[21] Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
Motzer, Robert J.
Choueiri, Toni K.
Powles, Thomas
Burotto, Mauricio
Bourlon, Maria Teresa
Hsieh, James J.
Maruzzo, Marco
Shah, Amishi Yogesh
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Porta, Camillo
Goh, Jeffrey C.
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Gupta, Saurabh
Apolo, Andrea B.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[22] Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
Apolo, Andrea B.
Powles, Thomas
Burotto, Mauricio
Bourlon, Maria Teresa
Hsieh, James J.
Basso, Umberto
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Gurney, Howard
Kessler, Elizabeth R.
Retz, Margitta
George, Saby
Escudier, Bernard
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Tannir, N. M.
McDermott, D. F.
Burotto, M.
Choueiri, T. K.
Hammers, H. J.
Plimack, E. R.
Porta, C. G.
George, S.
Powles, T. B.
Donskov, F.
Gurney, H.
Kollmannsberger, C. K.
Grimm, M-O.
Tomita, Y.
Rini, B. I.
McHenry, M. B.
Lee, C-W.
Escudier, B.
ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
[24] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Tannir, Nizar M.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael Anthony
McDermott, David F.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Bracarda, Sergio
Tykodi, Scott S.
Powles, Thomas
Rini, Brian I.
Tomita, Yoshihiko
McHenry, M. Brent
Mekan, Sabeen Fatima
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[25] Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
Tarigopula, Vivek
INDIAN JOURNAL OF UROLOGY, 2022, 38 (04) : 317 - 318
[26] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Albiges, L.
Tannir, N.
Burotto, M.
McDermott, D. F.
Plimack, E. R.
Barthelemy, P.
Porta, C. G.
Powles, T. B.
Donskov, F.
George, S.
Kollmannsberger, C.
Gurney, H.
Grimm, M-O.
Tomita, Y.
Castellano Gauna, D.
Rini, B. I.
Choueiri, T. K.
Saggi, S. S.
McHenry, M. B.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
[27] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Janjigian, Yelena Y.
Ajani, Jaffer A.
Moehler, Markus
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Karamouzis, Michalis
Bruges, Ricardo
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshi
Tehfe, Mustapha
Zander, Thomas
Kowalyszyn, Ruben
Pazo-Cid, Roberto
Schenker, Michael
Feeny, Kynan
Wang, Rui
Lei, Ming
Chen, Clara
Nathani, Raheel
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
[28] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
Cella, David
Motzer, Robert J.
Suarez, Cristina
Blum, Steven, I
Ejzykowicz, Flavia
Hamilton, Melissa
Wallace, Joel F.
Simsek, Burcin
Zhang, Joshua
Ivanescu, Cristina
Apolo, Andrea B.
Choueiri, Toni K.
LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
[29] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Motzer, Robert
Rini, Brian, I
McDermott, David F.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael A.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Neiman, Victoria
Bracarda, Sergio
Tykodi, Scott S.
Barthelemy, Philippe
Leibowitz-Amit, Raya
Plimack, Elizabeth R.
Oosting, Sjoukje F.
Redman, Bruce
Melichar, Bohusiav
Powles, Thomas
Nathan, Paul
Oudard, Stephan
Pook, David
Choueiri, Toni K.
Donskov, Frede
Grimm, Marc-Oliver
Gurney, Howard
Heng, Daniel Y. C.
Kollmannsberger, Christian K.
Harrison, Michael R.
Tamita, Yoshihiko
Duran, Ignacio
Gruenwold, Viktor
McHenry, M. Brent
Mekan, Sabeen
Tannir, Nizar M.
LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
[30] Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Antonia, S.
Gettinger, S.
Borghaei, H.
Goldman, J. W.
Brahmer, J.
Ready, N.
Gerber, D.
Chow, L.
Juergens, R.
Laurie, S.
Shepherd, F.
Li, X.
Li, A.
Geese, W.
Hellmann, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S458 - S458

← 1 2 3 4 5 →